ACADVL (Acyl-CoA Dehydrogenase Very Long Chain)

This study systematically reveals the critical protective role of EGLN1 in high BMI-associated CRC and underscores its value as a potential drug target. EGLN1 influences CRC pathogenesis by modulating multiple dimensions, including the hypoxia response, energy metabolism, the immune microenvironment, and the gut microbiota. The natural compound Cianidanol, as a modulator of EGLN1, demonstrated significant anti-tumor activity in vitro. These findings provide new insights into the molecular mechanisms linking obesity and CRC and establish a theoretical foundation for developing precision therapeutic strategies targeting EGLN1.

Crucially, this AMPK/KLF4/ACADVL network operates independently of BRCA status, proposing targeted therapy for chemoresistant non-BRCA mutant TNBC. Our findings redefine TNBC metabolic plasticity through transcriptional-metabolic crosstalk, offering combinatorial therapeutic paradigms against metabolic adaptation.

Finally, we found that COX10, one of 6 MMRGs, could inhibit the malignant progression of ESCC in vitro. In summary, we constructed a clinical prognosis model based on 6 MMRGs and clinical features which can accurately predict the prognosis of ESCC patients.

Collectively, these findings suggest that there is a strong connection between FAM and HBV-associated HCC, indicating a potential therapeutic strategy targeting FAM to block the accumulation of Tregs into the tumor microenvironment of HBV-associated HCC.

An OS-related prognostic model can accurately provide the prognosis of osteosarcoma patients, and may help identify suitable candidates for immunotherapy.

Downstream inhibition of MAZ-NF1 chimeric transcript in an ALK- ALCL PDX using MEK-inhibitor AZD6244 produced a delay in tumor growth in-vivo...Finally, we trained a predictive model based on RNAseq data and viability upon drug exposure and found gene sets predicting response to specific compounds (i.e., ruxolitinib and belinostat)...1D) and showed close correspondence with patients' responses to various drugs, including chemotherapy (CHOP) as well as targeted agents (ALK-inhibitor crizotinib, JAK-inhibitor ruxolitinib, CD30-drug conjugate brentuximab-vedotin). In addition, we tested novel compounds emerging from the drug screenings including JAK/SYK inhibitor cerdulatinib and CDK9 inhibitor AZD4573: mice treated with the combination of the two drugs showed significantly better progression-free survival compared to single agents... We generated the largest TCL PDX bio-repository accounting for >90 models of different subtypes. PDXsmimicked donor lymphomas phenotypically and genotypically. We discovered novel driver fusions, oncogenic mutations, clonal evolution patterns, innovative therapeutics/combinations and response predictors.